Adds share move in paragraph 2, adds analyst comments in paragraph 5 & 6

By Sahil Pandey

March 10 (Reuters) - Medical device maker Medtronic MDT.N said on Tuesday it would buy U.S.-based Scientia Vascular in a deal valued at $550 million, expanding its line-up of products used in stroke care.

Shares of the company were down more than 1% in early trading.

Here are some details:

• Scientia, based in Salt Lake City with about 310 employees, makes guidewires and catheters used to navigate blood vessels in the brain.

• These guidewires and catheters can be seamlessly integrated into Medtronic's existing suite of neurovascular products, the medical device maker said.

• The deal positions Medtronic with a full suite of products and supports procedures across both hemorrhagic and acute ischemic stroke, said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business.

• Medtronic expects the deal to close in the first half of fiscal 2027.

• Analysts at Leerink Partners said the deal supports Medtronic's broader plan to lift growth through acquisitions and reflects confidence in Scientia's underlying technology.

• Evercore ISI said the acquisition is a well‑fitting tuck‑in that strengthens Medtronic's stroke portfolio and aligns with its existing neurovascular devices.

• The company also expects the deal to be minimally dilutive to its adjusted earnings in 2027 and accretive thereafter.

• Medtronic added that there could be potential earn-out and milestone payments post-acquisition, but did not disclose any further details on the same.